IKNA Quote, Financials, Valuation and Earnings

Nanoviricides has a net margin of -- compared to Ikena Oncology's net margin of --. Ikena Oncology's return on equity of -- beat Nanoviricides's return on equity of --.

Ikena Oncology has a consensus price target of $2.00, signalling upside risk potential of 68.07%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 327.63%. Given that Nanoviricides has higher upside potential than Ikena Oncology, analysts believe Nanoviricides is more attractive than Ikena Oncology.

Ikena Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

Ikena Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ikena Oncology pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Ikena Oncology quarterly revenues are --, which are smaller than Nanoviricides quarterly revenues of --. Ikena Oncology's net income of -$8.6M is lower than Nanoviricides's net income of -$2.2M. Notably, Ikena Oncology's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ikena Oncology is 6.27x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -- compared to Ikena Oncology's net margin of --. Ikena Oncology's return on equity of -- beat Oragenics's return on equity of --.

Ikena Oncology has a consensus price target of $2.00, signalling upside risk potential of 68.07%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 733.33%. Given that Oragenics has higher upside potential than Ikena Oncology, analysts believe Oragenics is more attractive than Ikena Oncology.

Ikena Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

Ikena Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ikena Oncology pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Ikena Oncology quarterly revenues are --, which are smaller than Oragenics quarterly revenues of --. Ikena Oncology's net income of -$8.6M is lower than Oragenics's net income of -$2.2M. Notably, Ikena Oncology's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ikena Oncology is 6.27x versus 1.15x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Ikena Oncology's net margin of --. Ikena Oncology's return on equity of -- beat Theriva Biologics's return on equity of --.

Ikena Oncology has a consensus price target of $2.00, signalling upside risk potential of 68.07%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1399.25%. Given that Theriva Biologics has higher upside potential than Ikena Oncology, analysts believe Theriva Biologics is more attractive than Ikena Oncology.

Ikena Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

Ikena Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ikena Oncology pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Ikena Oncology quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Ikena Oncology's net income of -$8.6M is lower than Theriva Biologics's net income of -$4.3M. Notably, Ikena Oncology's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ikena Oncology is 6.27x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

Traws Pharma has a net margin of -- compared to Ikena Oncology's net margin of -14868.42%. Ikena Oncology's return on equity of -- beat Traws Pharma's return on equity of -124.39%.

Ikena Oncology has a consensus price target of $2.00, signalling upside risk potential of 68.07%. On the other hand Traws Pharma has an analysts' consensus of -- which suggests that it could grow by 322.54%. Given that Traws Pharma has higher upside potential than Ikena Oncology, analysts believe Traws Pharma is more attractive than Ikena Oncology.

Ikena Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Traws Pharma has a beta of 1.588, suggesting its more volatile than the S&P 500 by 58.788%.

Ikena Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Traws Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ikena Oncology pays -- of its earnings as a dividend. Traws Pharma pays out -- of its earnings as a dividend.

Ikena Oncology quarterly revenues are --, which are smaller than Traws Pharma quarterly revenues of $57K. Ikena Oncology's net income of -$8.6M is lower than Traws Pharma's net income of $21.5M. Notably, Ikena Oncology's price-to-earnings ratio is -- while Traws Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ikena Oncology is 6.27x versus 20.08x for Traws Pharma. Usually stocks with elevated PS ratios are considered overvalued.